A double-blind, placebo-controlled study of anti-CD5 immunoconjugate in patients with rheumatoid arthritis. The Xoma RA Investigator Group.

Journal Article (Clinical Trial;Journal Article;Multicenter Study)

OBJECTIVE: To evaluate the efficacy of an anti-CD5 ricin-linked immunoconjugate (CD5-IC) in patients with rheumatoid arthritis (RA). METHODS: A total of 104 evaluable patients were enrolled in a multicenter, double-blind, multiple-dose, placebo-controlled study of CD5-IC. RESULTS: Treatment with CD5-IC in doses up to 8 mg/m2/day for 4 days in 1 month failed to produce marked or prolonged T cell depletion and was no more effective than placebo in ameliorating disease manifestations. An unexpectedly high placebo response was observed in 48% of the patients. Adverse events were correlated with the dose of CD5-IC, but the treatment was generally well-tolerated. CONCLUSION: At the doses used in this study, CD5-IC was ineffective for treating RA.

Full Text

Duke Authors

Cited Authors

  • Olsen, NJ; Brooks, RH; Cush, JJ; Lipsky, PE; St Clair, EW; Matteson, EL; Gold, KN; Cannon, GW; Jackson, CG; McCune, WJ; Fox, DA; Nelson, B; Lorenz, T; Strand, V

Published Date

  • July 1996

Published In

Volume / Issue

  • 39 / 7

Start / End Page

  • 1102 - 1108

PubMed ID

  • 8670317

International Standard Serial Number (ISSN)

  • 0004-3591

Digital Object Identifier (DOI)

  • 10.1002/art.1780390705


  • eng

Conference Location

  • United States